Barclays analyst Gena Wang upgraded Kodiak Sciences (KOD) to Equal Weight from Underweight with a price target of $17, up from $7. The firm says Roche’s Phase 2 vamikibart plus ranibizumab data in diabetic macular edema provide “important clinical validation” Kodiak’s for KSI-101. The clinical profiles are largely comparable and key opinion leader feedback suggest a low bar for practice adoption with KSI-101, the analyst tells investors in a research note.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KOD:
- Pfizer to acquire Metsera, Oracle names new CEOs: Morning Buzz
- Promising Drug Pipeline and Strong Financial Position Drive Buy Rating for Kodiak Sciences
- Kodiak Sciences initiated with a Buy at Jefferies
- Kodiak Sciences announces new data from APEX study of KSI-101
- Kodiak Sciences price target raised to $7 from $4 at Barclays